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Abstract
Background: Among patients with an implanted cardiac implantable electronic device (CIED), ipsi-
lateral upper extremity vein stenosis or occlusion (VSO) is observed more frequently than in the general 
population. However, there are no data available concerning the relationship between hemostatic mark-
ers (and their dynamics) and the occurrence of VSO. The aim of this study was to assess the predictive 
value of beta-thromboglobulin, the von Willebrand factor (vWF), fibrynogen and D-dimer for VSO 
development among first time CIED recipients.
Methods: This is a single-center, prospective study of consecutive first time CIED recipients without 
upper extremity VSO in baseline ultrasound examination. Biochemical data were collected from all the 
patients before CIED implantation (first measuring), up to 7 days subsequent (second measuring) and 
6 months after the operation (third measuring). Primary endpoint was defined as the presence of upper 
extremity VSO at the implantation site during the ultrasound examination 6 months after the operation. 
Results: The study included 71 patients (mean age 73.1 ± 10.5 years; 39 [55%] male). The incidence 
of VSO within 6-months follow up was 21.1%. Average concentrations of hemostatic markers increased 
significantly in all patients immediately after CIED implantation. Serial hemostatic marker concentra-
tions were similar in patients who met or did not meet the primary endpoint, apart from vWF. The mean 
concentration was significantly elevated in the group of 15 patients who reached the primary endpoint 
(p = 0.032).
Conclusions: A significant increase in vWF concentration at 6 months post implantation may be  
a marker for VSO occurrence. (Cardiol J XXXX; XX, X: xx–xx)
Key words: cardiac implanted electronic devices, vein stenosis or occlusion, hemostatic 
markers
Introduction
Among patients implanted with a cardiac 
implantable electronic device (CIED), ipsilateral 
upper extremity vein stenosis or occlusion (VSO) 
is observed more frequently than in the general 
population and occurs in 14–64% of patients with 
CIED [1–3]. Although VSO is usually asymptomatic 
it can lead to upper extremity edema, paresthesia 
or pain and limits CIED upgrade. 
Currently, several mechanisms of VSO forma-
tion are suggested. The most frequently mentioned 
one is the thromboembolic mechanism [4, 5]. The 
postulated thromboembolic mechanism of VSO 
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formation prompts the search for biochemical 
indicators of pro-thrombotic activity, which would 
correlate with the risk of VSO. 
The concentration of D-dimers is a biochemi-
cal marker of the thromboembolic process. The 
precursor of D-dimers is fibrinogen: one of the 
coagulation system proteins. It seems that among 
patients after CIED implantation, the concentra-
tion of D-dimers and fibrinogen should be higher 
in patients with VSO [6]. Platelet activation results 
in secretion of many clotting activators, including 
beta-thromboglobulin (beta-TG). The von Wille-
brand factor (vWF), a glycoprotein involved in the 
hemostasis process, prevents the degradation of 
factor VIII of the coagulation pathway, promoting 
the formation of connections between collagen fib-
ers, glycoproteins of the intercellular matrix and 
endothelial cells and blood platelets. 
However, there are no specific data available 
concerning relationship between concentrations of 
the aforementioned hemostatic markers (and their 
dynamic) and the occurrence of VSO after CIED 
implantation. The aim of this study was to assess 
the predictive value of beta-TG, vWF, fibrynogen 
and D-dimer concentrations for VSO occurrence 
among first-time CIED recipients.
Methods
Study population
A single-center, prospective study was per-
formed of consecutive first-time CIED recipients 
hospitalized in the documented department. 
Patients included were those with:
 — qualification for first-time intravenous implan-
tation of the CIED system;
 — written, informed consent to participate in 
the study.
Patients excluded were those with:
 — upper extremity, shoulder girdle or jugular 
vein stenosis confirmed by preoperative im-
aging;
 — venous compression syndromes of the upper 
extremity (thoracic outlet syndrome, cervical 
rib, compressive soft tissue tumors);
 — thrombophilia;
 — previous intervention on venous system at the 
intended implantation site.
Clinical assessment and follow-up
Each patient underwent an ultrasound exami-
nation to assess the condition of the venous system 
of the upper extremity, shoulder girdle and jugular 
veins before the planned operation and 6 months 
after the operation. The assessment of jugular 
veins and veins of shoulder girdle were performed 
in the supine position, while radiopaque and axil-
lary veins were additionally assessed in the sitting 
position. A duplex Doppler mode consisting of 
a real-time B-mode image with a color-flow Dop-
pler overlay was used for assessing the morphology 
and venous flow. All ultrasound examinations were 
carried out by experienced echocardiographers (all 
certified with the second-degree accreditation in 
echocardiography of the Echocardiography Work-
ing Group of the Polish Cardiac Society) using the 
Philips EnVisor C (Philips Electronics NV, Neth-
erlands). The tests were examined using a 5–13 
Mega-Hertz array transducer in both longitudinal 
and transverse sections.
All clinical conditions analyzed in the study, 
like diabetes or prediabetes, chronic heart failure, 
arterial hypertension, atrial fibrillation or atrial flut-
ter, cancer, previous stroke or transient ischemic 
attack, were assessed based on subject medical 
history and in accordance with current guidelines. 
The procedure of CIED implantation was 
performed in a reference cardiology unit by an 
expected electrophysiologist. For each subject the 
first-choice procedure to gain vascular access was 
venesection of cephalic vein. If this was unsuccess-
ful, a subclavian vein puncture under ultrasound 
imaging was performed. Patient characteristics due 
to the number of implanted leads and type of vas-
cular access was presented in a previous paper [7]. 
The concentrations of beta-TG, vWF, fibryno-
gen and D-dimer were measured before CIED 
implantation (first measuring), up to 7 days sub-
sequent (second measuring) and 6 months after 
the operation (third measuring). Manual EIA kits 
were used to measure beta-TG and vWF (Shang-
hai Sunred Biological Technology Co, Shanghai, 
China). Roche Diagnostics laboratory kits were 
used in order to conduct D-dimer and fibrynogen 
tests using Cobas 6000 analyzer.
Study endpoints
Primary endpoint was defined as the presence 
of VSO in the vein system of the upper extremity, 
shoulder girdle or jugular vein at the implantation 
site during the ultrasound examination 6 months 
after the operation. For veins accessible to direct 
insonation, the criteria of noncompressibility, 
visualization of echogenic intravascular mass, and 
the absence of respiratory variation were used 
(subclavian vein). For veins inaccessible to direct 
inosonation, the criterion of monophasic flow at 
the stenosis site with no retrograde wave or no 
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color signal or flow in the vessel lumen was used 
(middle part of subclavian, brachiocephalic vein) 
to detect VSO [8, 9].
Statistical analysis
Statistical analysis was performed using Sta-
tistica v. 12. Quantitative variables are expressed as 
mean ± standard deviation and median (interquar-
tile range). Categorical variables are presented as 
an exact number and percentage of patients. Differ-
ences between two groups for continuous variables 
were tested by the Mann-Whitney U-test. The 
comparisons of categorical variables were analyzed 
using the c2 independence test. Two-way tables 
were assessed with the c2 test with double-sided 
Fisher exact test due to a limited number of pa-
tients. A p value < 0.05 was defined as statistically 
significant. The dynamics of biochemical marker 
changes were assessed using the Friedman test. 
Post hoc analysis with the Wilcoxon signed ranks 
test was performed using the Bonferroni correction 
for multiple comparisons (1 vs. 2, 2 vs. 3, 1 vs. 3 
measuring point), resulting in a significance level 
set at p < 0.017.
Results
The study population consisted of 71 patients 
(mean age 73.1 ± 10.5 years; 39 [55%] male). 
Detailed patient characteristics were summarized 
in Supplemental Content (Suppl. Table S1). 
Implanted device systems comprised: cardio-
verter-defibrillator (n = 26), single-chamber or 
dual-chamber pacemakers (n = 34) and cardiac 
resynchronization therapy (n = 11). The incidence 
of VSO within 6-month follow up was 15 (21.1%) 
patients.
The mean concentrations of biochemical mar-
kers and their dynamics assessed at the 1st, 2nd 
and 3rd measuring points in the whole study group 
are presented in Table 1 and Figure 1. The aver-
age concentration of each biochemical marker 
increased significantly between the 1st and the 2nd 
measuring points.
The average values of biochemical markers at 
all measuring points were similar among patients 
who met or did not meet primary endpoint, except 
for vWF concentrations at the 3rd measuring point. 
The average concentration of the vWF 6 months 
after the CIED implantation was significantly 
greater in the group of patients with VSO than in 
the other subjects (p = 0.03). It was due to an ad-
ditional increase of vWF concentration between the 
2nd and 3rd measuring point observed only among 
patients with VSO (Fig. 2). The mean concentra-
tions of biochemical markers and their dynamics 
in subgroups with and without primary endpoint 
were presented in Table 2 and Figure 2.
Table 1. The mean concentrations of biochemical markers measured at 1st, 2nd and 3rd measuring point 
in the whole study group.
Hemostatic marker Mean ± SD Median (IQR)
Fibrynogen [mg/dL]
1st measuring 351.5 ± 81.8 343 (86–530)
2nd measuring 424.3 ± 95.5 408 (178–627)
3rd measuring 404.2 ± 98 391 (212–619)
D–dimer [mg/dL]
1st measuring 723.5 ± 664 458 (170–3210)
2nd measuring 1252.1 ± 1068.3 875 (326–6586)
3rd measuring 1021.4 ± 778.5 766 (230–3890)
von Willebrand factor [µg/L]
1st measuring 13.26 ± 5.55 12.25 (3.78–27.56)
2nd measuring 18.35 ± 9.29 16.64 (5.37–66.55)
3rd measuring 19.56 ± 11.11 17.38 (0.32–56.86)
Beta–thromboglobulin [µg/L]
1st measuring 14.24 ± 5.77 13.43 (3.42–30.37)
2nd measuring 18.12 ± 6.93 18.18 (2.21–34.18)
3rd measuring 17.86 ± 6.5 10.06 (5.61–32.7)
Continuous and ordinal variables are shown as median (interquartile range [IQR]) and as mean ± standard deviation (SD).
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Figure 1. The mean concentrations of biochemical markers measured at 1st, 2nd and 3rd measuring point in the whole 
study group; beta-TG — beta-thromboglobulin; vWF — the von Willebrand factor; NS — non-significant.
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Table 2. The mean concentrations of biochemical markers measured at 1st, 2nd and 3rd measuring point 
among patients who met or did not meet the primary endpoint.
Hemostatic marker Endpoint Non-endpoint p
Mean ± SD Median (IQR) Mean ± SD Median (IQR)
Fibrynogen [mg/dL]
1st measuring 347 ± 87.5 313 (244–530) 352.7 ± 81 352 (86–481) 0.61
2nd measuring 410.7 ± 91.3 388 (264–564) 427.9 ± 97 413.5 (178–627) 0.54
3rd measuring 398 ± 100.6 376 (234–591) 405.9 ± 98.2 396.5 (212–619) 0.82
D-dimer [mg/dL]
1st measuring 762.9 ± 864.6 424 (170–3210) 712.9 ± 608.5 458.5 (170–2908) 0.58
2nd measuring 1247.3 ± 1132.6 825 (357–4506) 1253.4 ± 1061.1 929 (326–6586) 0.71
3rd measuring 1091.1 ± 949.7 736 (400–3890) 1002.8 ± 734.8 766 (230–3148) 0.92
Von Willebrand factor [µg/L]
1st measuring 14.62 ± 5.77 15.29 (4.9–23.3) 12.89 ± 5.49 11.7 (3.78–27.56) 0.31
2nd measuring 16.54 ± 6.85 15.7 (8.63–30.6 18.83 ± 9.84 16.92 (5.37–66.56) 0.41
3rd measuring 23.71 ± 10.14 18.79 (14.67–42.5) 18.45 ± 11.19 16.47 (0.32–56.86) 0.32
Beta-thromboglobulin [µg/L]
1st measuring 16.2 ± 8.58 13.42 (3.42–30.37) 13.72 ± 4.72 13.52 (4.09–25.75) 0.64
2nd measuring 18.31 ± 8 19.01 (2.21–34.18) 18.07 ± 6.7 17.59 (3.03–34.14) 0.77
3rd measuring 18.11 ± 6.63 17.07 (7.95–30.63) 17.79 ± 6.53 17.04 (5.61–32.7) 0.91
Continuous variables are shown as  median (interquartile range [IQR]) and as mean ± standard deviation (SD). P values are given for differ-
ences between the patients with and without primary endpoint.
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The observation that anticoagulation therapy 
or presence of cancer was not associated with an 
increased risk for primary endpoint occurrence as 
described in a previous publication [7].
Discussion
The present paper was focused on simultane-
ous analysis of the dynamics of concentrations 
Figure 2. The mean concentrations of biochemical markers measured at the 1st, 2nd and 3rd measuring point among 
patients who met or did not meet the primary endpoint; beta-TG — beta-thromboglobulin; vWF — the von Willebrand 
factor; NS — non-significant.
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of biochemical markers of inflammation (fibrino-
gen), coagulation activity (D-dimers) and platelet 
activation (vWF and beta-TG), in the population 
of first-time CIED recipients. According to avail-
able research, this is the first report describing 
dynamics of hemostatic markers among first-time 
CIED recipients followed-up by up to 6 months and 
their relationship with VSO, one of the most com-
mon complications of the lead placement into the 
vascular system. It should be emphasized that this 
report is important with regard to ensuring a better 
understanding of the mechanism of VSO occur-
rence and its prediction after CIED implantation.
Nevertheless, in starting the discussion, read-
ers may be kindly forwarded to a previous paper 
presenting results of comparisons between subjects 
with and without study endpoints [6]. As it is a real-
life population of first time CIED recipients, patients 
were included who had clinical conditions like atrial 
fibrillation, arterial hypertension, chronic heart fail-
ure, previous stroke or cancer. Though, during the 
follow up neither antithrombotic or anticoagulant 
treatment nor any of these conditions significantly 
increased the prevalence of VSO. Moreover, the 
presence of diabetes or prediabetes reduced the risk 
of VSO supporting the thesis of the inductive influ-
ence of inflammation. Reported observations built a 
multivariable prognostic model for VSO occurrence 
in the previously mentioned paper [7]. 
The procedure of CIED implantation, with 
intervention in the vascular system, initiated a sig-
nificant increase in the concentration of biochemi-
cal markers. This is understandable considering 
the intervention itself (incision or puncture of a 
large venous vessel and preparation of the device 
pocket). However, only the vWF concentration, 
measured six months after the CIED implantation 
was significantly increased among patients who 
reached the primary endpoint. Moreover, the only 
marker that its concentration increased between 
the 2nd and 3rd measuring point among patients 
with VSO was vWF. It is worth mentioning that 
VSO occurrence is mostly associated with vessel 
trauma and subsequent inflammation [10]. This is 
consistent with the literature as vWF is synthe-
sized in endothelium and is realized due to cell 
injury [11]. Moreover, inflammatory leukocytes 
release oxidizing agents that can render vWF more 
stable, with enhanced platelet binding, explaining 
higher concentrations of vWF among patients with 
VSO [12].
Results of this study propose possible clini-
cal implantation of serial vWF measurement in a 
screening for VSO among first-time CIED recipi-
ents. Significant increases of vWF concentration 
between 7th day and 6th month follow-up from CIED 
implantation may identify patients with VSO. Still, 
as this is a pilot prospective study, additional ob-
servations in this field are required.
The fibrinogen and D-dimer concentrations 
have significantly decreased between 2nd and 3rd 
measuring points regardless of the occurrence 
of VSO. Also, the beta-TG concentration was re-
duced within 6 months (but not significantly). It 
is an important finding considering a conviction 
that promoted hemostasis and thrombosis should 
result in increase of fibrin-degradation-product 
concentration.
Finally, it is worth exploring the role of beta-
TG. This protein is stored in alpha-granules of 
platelets and is released in large amounts after 
platelet activation. It acts as a megakaryocyte 
maturation factor and helps in regulating platelet 
production, thus it has been recognized as a marker 
for activated platelets. Current studies suggest that 
an increased level of activated platelets, measured 
by higher plasma levels of beta-TG, is associated 
with increased risk of incidence of cardiovascular 
disease [13, 14]. For instance, the Plicner et al. [15] 
study included 108 consecutive patients undergo-
ing coronary artery bypass grafting, demonstrated 
that increased platelet activation contributes to the 
occurrence of perioperative myocardial infarction 
in an early postoperative period. However, Kubota 
et al. [16], a study with 746 participants, do not sup-
port the hypothesis that higher concentrations of 
beta-TG reflect an increased risk of cardiovascular 
endpoints in the general population.
Limitations of the study
The present study is single-centered and 
nonrandomized. The size of the study population 
was the result of the test methodology (the study 
group encompassed only a population of first 
time CIED recipients) and the cost of biochemical 
markers and limited funding. Moreover, the study 
population is homogeneous as all of patients who 
underwent their first cardiac device implantation and 
were assessed exactly at 6 months postoperatively. 
Another limitation of this study is the single image 
approach to diagnose VSO. However, color Doppler 
ultrasonography is a non-invasive method with high 
sensitivity (80%) and a specificity (90–100%) for 
detecting VSO [17, 18]. Another limitation is the fact 
that no attempt was made to study the ratio between 
the caliber of the vein and number of leads inserted.
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Conclusions
All biochemical hemostatic marker levels 
increased significantly in response to transvenous 
CIED insertion and the presence of electrodes 
in the venous system. A significant increase in 
vWF level at 6 months post implantation may be a 
marker of VSO occurrence.
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